Home » Stocks » CRVS

Corvus Pharmaceuticals, Inc. (CRVS)

Stock Price: $4.06 USD -0.07 (-1.69%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $4.14 +0.08 (1.97%) Jan 15, 5:33 PM
Market Cap 113.93M
Revenue (ttm) n/a
Net Income (ttm) -44.39M
Shares Out 29.50M
EPS (ttm) -1.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $4.06
Previous Close $4.13
Change ($) -0.07
Change (%) -1.69%
Day's Open 4.30
Day's Range 4.00 - 4.33
Day's Volume 257,518
52-Week Range 1.74 - 5.98

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

Updated interim d ata from CPI-818 's p hase 1/1b c linical t rial provide evidence supporting its potential as a treatment for T cell lymphomas

GlobeNewsWire - 1 month ago

Includes updated data from CPI-818 phase 1/1b trial and pre-clinical results supporting use in autoimmune lymphoproliferative syndrome (ALPS) Includes updated data from CPI-818 phase 1/1b tria...

GlobeNewsWire - 2 months ago

Data shows CPI-006 provide d enhanced and prolonged polyclonal humoral immunity to SARS - CoV - 2

GlobeNewsWire - 2 months ago

Data to be presented in a poster and an oral session “ Hot Topic Symposium : COVID-19 and Cancer ” at SITC

GlobeNewsWire - 2 months ago

Company to host R&D Symposium webcast November 12, 2020 at 11:00 am ET to highlight COVID-19 program and provide updates on its cancer programs Company to host R&D Symposium webcast November 1...

Seeking Alpha - 3 months ago

10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million.

Other stocks mentioned: INCY, TXG, ZLAB
24/7 Wall Street - 3 months ago

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) shares were sharply higher on Monday after the company announced updated data from its ongoing early-stage study in patients with COVID-19.

GlobeNewsWire - 3 months ago

Angel ’s pipeline will feature Corvus’ three clinical-stage candidates – ciforadenant, CPI-006 and CPI-818 – and its preclinical BTK inhibitor program

GlobeNewsWire - 3 months ago

Enrollment in first three cohorts complete; final cohort now enrolling with plans to initiate a pivotal study before year-end

GlobeNewsWire - 4 months ago

Data is part of Genentech’s MORPHEUS umbrella program and covers patients with resistant/refractory NSCLC treated with ciforadenant in combination with atezolizumab

GlobeNewsWire - 4 months ago

Dr. Mitchell adds significant experience in cancer care, research and healthcare delivery as the Company advances pipeline into later-stage clinical development Dr. Mitchell adds significant e...

GlobeNewsWire - 4 months ago

Characterization of novel immunotherapy approach with CPI-006 and details of COVID-19 clinical trial results submitted for publication online at medRxiv.org

GlobeNewsWire - 4 months ago

BURLINGAME, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the fo...

GlobeNewsWire - 5 months ago

BURLINGAME, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 202...

GlobeNewsWire - 5 months ago

Provides Update on CPI-006 Phase 1 COVID-19 Study

GlobeNewsWire - 5 months ago

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

GlobeNewsWire - 6 months ago

VANCOUVER, British Columbia, July 16, 2020 (GLOBE NEWSWIRE) -- Corvus Gold Inc. (“Corvus Gold” or the “Company”) - (TSX: KOR, OTCQX: CORVF) announces it has received positive drilling result...

Zacks Investment Research - 6 months ago

Corvus Pharmaceuticals (CRVS) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

24/7 Wall Street - 6 months ago

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) made a big splash on Tuesday by announcing that it would initiate an early-stage immunotherapy study in patients with COVID-19.

Zacks Investment Research - 6 months ago

Shares of Corvus (CRVS) rise as it commences a phase I study to investigate a novel immunotherapy approach for patients with COVID-19.

24/7 Wall Street - 6 months ago

Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) watched the COVID-19 stock bump play out in Tuesday’s session as this company joins the ever-growing list of coronavirus stocks.

Benzinga - 6 months ago

Shares of Corvus Pharmaceuticals Inc (NASDAQ: CRVS) are advancing strongly Tuesday following an announcement concerning its foray into COVID-19 treatment.

Market Watch - 6 months ago

Shares of Corvus Pharmaceuticals Inc. CRVS, +77.73% soared 81.2% in trading on Tuesday after the company said it launched an open-label Phase 1 clinical trial testing an experimental monoclona...

GlobeNewsWire - 6 months ago

Approach stimulates immune response by activating B cells to enhance antibody production

GlobeNewsWire - 7 months ago

Elucidation of CD68 as a Downstream Target of Adenosine Refines Adenosine Gene Signature into a Practical Pathology Test Provides Opportunity to Further Enrich Patient Selection for Responders

Zacks Investment Research - 7 months ago

Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 8 months ago

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 10 months ago

Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT

GlobeNewsWire - 10 months ago

BURLINGAME, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-st...

Seeking Alpha - 11 months ago

Corvus Pharmaceuticals: Turnaround In Progress, Multiple Readouts Ahead

GlobeNewsWire - 1 year ago

Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy Selective ITK inhibitor was well tolerated with demonstration of specific target occupancy

GlobeNewsWire - 1 year ago

  SITC presentation builds on data at ASCO in June, adding evidence supporting a new immuno-oncology approach with CPI-006 via activation of immune cells and the inhibition of adenosine produc...

Seeking Alpha - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT

Seeking Alpha - 1 year ago

CRVS stock price has reached cash value, giving no value to its three drugs currently in clinical trials.

Seeking Alpha - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

The stock has gained 70% during the past month due to significant insider buying.

Seeking Alpha - 1 year ago

Shares have lost over a third of their value since my initial article.

Seeking Alpha - 1 year ago

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Today, it is Corvus Pharmaceuticals that is in the spotlight as we take a deeper look at this small cap developmental concern.

About CRVS

Corvus Pharmaceuticals, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase Ib/2 clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of adenosine and stimulate various immune cells, as well as Phase I clinical tr... [Read more...]

Industry
Biotechnology
IPO Date
Mar 23, 2016
CEO
Richard Miller
Employees
52
Stock Exchange
NASDAQ
Ticker Symbol
CRVS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for CRVS stock is "Strong Buy." The 12-month stock price forecast is 9.20, which is an increase of 126.60% from the latest price.

Price Target
$9.20
(126.60% upside)
Analyst Consensus: Strong Buy